Drug Transporter (DT) Information

General Information of DT
DT ID DTD0030
Gene Name SLCO1B3
Protein Name Organic anion transporting polypeptide 1B3
Gene ID
28234
UniProt ID
Q9NPD5
TCDB ID
2.A.60.1.12
3D Structure

Modelled DT Structure

Method: multi-sequence alignment based machine learning

Detail: Structure Info

Synonyms LST-2; LST-3TM13; LST2; LST3; Liver-specific organic anion transporter 2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; SLCO1B3; Solute carrier family 21 member 8; Solute carrier organic anion transporter family member 1B3
DT Family Organo Anion Transporter (OAT) Family ;
Tissue Specificity Highly expressed in liver, in particular atthe basolateral membrane of hepatocytes near the central vein. Notdetected in other tissues. Highly expressed in some cancer celllines derived from colon, pancreas, liver and gall bladder.
Function This transporter involved in the clearance of bile acids and organic anions from the liver. Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP).
Disease(s) Breast cancer [ICD-11: 2C60-2C6Z]
Diabetes [ICD-11: 5A10-5A14]
Dyslipidaemias [ICD-11: 5C8Z]
Heart failure [ICD-11: BD1Z]
Human immunodeficiency virus infection [ICD-11: 1C62.Z]
Osteoporosis [ICD-11: FB83.1]
Pemphigus vulgaris [ICD-11: EB40.0]
Urinary tract and skin bacteria infections [ICD-11: GC08]
Endogenous Substrate(s) Cholate; Cholecystokinin; 17Beta-glucuronosyl estradiol; Cholecystokinin 8; Monoglucuronosyl bilirubin; Tauroursodeoxycholate
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:          50 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Atorvastatin
 Approved Drug Info Hyperlipidaemia 5C8Z [1]
Bosentan
 Approved Drug Info Pulmonary arterial hypertension BB01.0 [2]
Cefmetazole
 Approved Drug Info Urinary tract and skin bacteria infections GC08 [3]
Cefoperazone
 Approved Drug Info Pseudomonas bacterial infections 1B92 [3]
Ceftriaxone
 Approved Drug Info Pneumonia CA40 [3]
Cerivastatin
 Approved Drug Info Hyperlipidaemia 5C8Z [1]
Cilostazol
 Approved Drug Info Intermittent claudication BD40.00 [4]
Crizotinib
 Approved Drug Info Non-small cell lung cancer 2C25 [5]
Dasatinib
 Approved Drug Info Multiple myeloma 2A83 [5]
Dehydroepiandrosterone sulfate
 Approved Drug Info Dyspareunia GA12 [6]
Diclofenac
 Approved Drug Info Osteoarthritis of knee FA01 [7]
Digoxin
 Approved Drug Info Arrhythmias BC60-BC9Z [8]
Docetaxel
 Approved Drug Info Lung cancer 2C25 [9]
Enalapril
 Approved Drug Info High blood pressure BA00 [10]
Erythromycin
 Approved Drug Info Pelvic inflammatory disease GA05 [11]
Estrone sulfate
 Approved Drug Info Menopausal symptoms MF32 [12]
Etoposide
 Approved Drug Info Testicular cancer 2C80 [12]
Fexofenadine
 Approved Drug Info Allergic rhinitis CA08.0 [13]
Fluorescein
 Approved Drug Info Ocular disease 9E1Z [14]
Fluvastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [15]
Gadobenate dimeglumine
 Approved Drug Info CNS imaging XD47Y1 [16]
Gefitinib
 Approved Drug Info Urethral cancer 2F78 [5]
Glutathione
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [17]
Hydroxyurea
 Approved Drug Info Chronic myelogenous leukemia 2A20.0 [18]
Imatinib
 Approved Drug Info Gastrointestinal stromal tumor 2B5B [5]
Indocyanine green
 Approved Drug Info Gastrointestinal disease DE2Z [19]
Liothyronine
 Approved Drug Info Hypothyroidism 5A00.2 [6]
Mesalazine
 Approved Drug Info Recurrent ventricular fibrillation BC71.1 [20]
Methotrexate
 Approved Drug Info Leukemia 2A60-2B33 [6]
Mycophenolate mofetil
 Approved Drug Info Pemphigus vulgaris EB40.0 [21]
Nateglinide
 Approved Drug Info Diabetes 5A10-5A14 [1]
Nilotinib
 Approved Drug Info Chronic myelogenous leukemia 2A20.0 [5]
Olmesartan medoxomil
 Approved Drug Info High blood pressure BA00 [22]
Ouabain
 Approved Drug Info Heart failure BD1Z [8]
Paclitaxel
 Approved Drug Info Breast cancer 2C60-2C6Z [23]
Pitavastatin
 Approved Drug Info Primary hyperlipidemia and mixed dyslipidemia 5C8Z [11]
Pitavastatin calcium
 Approved Drug Info Dyslipidaemias 5C8Z [24]
Pravastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [25]
Rifampicin
 Approved Drug Info Tuberculosis 1B1Z [26]
Romidepsin
 Approved Drug Info Cutaneous T-cell lymphoma 2B0Z [27]
Rosuvastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [28]
Sorafenib
 Approved Drug Info Pancreatic cancer 2C10 [5]
Sunitinib
 Approved Drug Info Imatinib-resistant gastrointestinal stromal tumor 2B5B [5]
Technetium (99MTC) mebrofenin
 Approved Drug Info Imaging of liver and gallbladder XD47Y1 [29]
Telmisartan
 Approved Drug Info High blood pressure BA00 [30]
Testosterone
 Approved Drug Info Osteoporosis FB83.1 [31]
Valsartan
 Approved Drug Info High blood pressure BA00 [32]
Vandetanib
 Approved Drug Info Thyroid gland tumours 2D10 [5]
Vemurafenib
 Approved Drug Info Thyroid cancer 2D10 [5]
Warfarin
 Approved Drug Info Atrial fibrillation BC81.3 [2]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            7 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Benzylpenicillin
 Phase 4 Drug Info Gram-positive bacteria infections 1A00-1H0Z [33]
Primovist
 Phase 4 Drug Info Lung cancer 2C25 [34]
Atrasentan
 Phase 3 Drug Info Endothelial dysfunction BE2Z [35]
Glycocholic acid
 Phase 3 Drug Info Bile acid synthesis defect 5C52.11 [8]
BQ-123
 Phase 2 Drug Info ST-Elevation myocardial infarction BA41.0 [8]
Danoprevir
 Phase 2 Drug Info Hepatitis C virus infection 1E50.2, 1E51.1 [1]
SN-38
 Phase 2 Drug Info Colon cancer 2B90.Z [9]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            3 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Sodium taurocholate
 Preclinical Drug Info Type 2 diabetes 5A11 [6]
Sincalide
 Preclinical Drug Info Discovery agent N.A. [36]
Taurocholic acid
 Terminated Drug Info Type 2 diabetes 5A11 [12]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            4 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Bile salt unspecific N.A. EM Info Unclear experiment used for identifying this EM [37]
Hormone metabolite unspecific N.A. EM Info Unclear experiment used for identifying this EM [37]
Thyroxine
5819
EM Info Unclear experiment used for identifying this EM [37]
Triiodothyronine
5920
EM Info Unclear experiment used for identifying this EM [37]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:          22 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Atorvastatin Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 0.73 microM [36]
Bosentan Approved Drug Info Chinese hamster ovary (CHO) cells-OATP1B3 Km = 141 microM [2]
Cilostazol Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 2.7 microM [4]
Estrone sulfate Approved Drug Info Chinese hamster ovary (CHO) cells-OATP1B3 Km = 58 microM [12]
Fexofenadine Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 108 microM [13]
Fluvastatin Approved Drug Info Madin-Darby canine kidney cells (MDCKII)-OATP1B3 Km = 7 microM [38]
Liothyronine Approved Drug Info Oocytes-OATP1B3 Km = 6.4 microM [6]
Mesalazine Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 77.4 microM [20]
Methotrexate Approved Drug Info Madin-Darby canine kidney (MDCK) cells-OATP1B3 Km = 39.4 microM [6]
Methotrexate Approved Drug Info Oocytes-OATP1B3 Km = 24.7 microM [6]
Olmesartan medoxomil Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 44.2 microM [22]
Olmesartan medoxomil Approved Drug Info Oocytes-OATP1B3 Km = 71.8 microM [39]
Paclitaxel Approved Drug Info Oocytes-OATP1B3 Km = 6.79 microM [23]
Pitavastatin calcium Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 3.25 microM [24]
Pitavastatin calcium Approved Drug Info Oocytes-OATP1B3 Km = 3.8 microM [40]
Rifampicin Approved Drug Info Oocytes-OATP1B3 Km = 2.3 microM [26]
Rosuvastatin Approved Drug Info Human cervical cancer cell line (Hela)-OATP1B3 Km = 9.8 microM [41]
Rosuvastatin Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 14.2 microM [28]
Telmisartan Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 0.81 microM [30]
Telmisartan Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 3.4 microM [42]
Valsartan Approved Drug Info Chinese hamster ovary (CHO) cells-OATP1B3 Km = 23.5 microM [43]
Valsartan Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 18.2 microM [32]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:          10 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Sodium taurocholate Preclinical Drug Info Oocytes-OATP1B3 Km = 5.8 microM [6]
Sincalide Preclinical Drug Info Oocytes-OATP1B3 Km = 11.1 microM [44]
Amanitin Investigative Drug Info Madin-Darby canine kidney cells (MDCKII)-OATP1B3 Km = 3.7 microM [33]
Bilirubin Investigative Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 0.5 microM [45]
Bilirubin Investigative Drug Info Oocytes-OATP1B3 Km = 0.0391 microM [46]
Bromsulphthalein Investigative Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 3.3 microM [45]
Bromsulphthalein Investigative Drug Info Oocytes-OATP1B3 Km = 0.4 microM [8]
Estradiol-17beta-glucuronide Investigative Drug Info Chinese hamster ovary (CHO) cells-OATP1B3 Km = 15.8 microM [12]
Estradiol-17beta-glucuronide Investigative Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 24.6 microM [24]
Fluo-3 Investigative Drug Info Chinese hamster ovary (CHO) cells-OATP1B3 Km = 3.1 microM [12]
References
1 FDA Drug Development and Drug Interactions
2 Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
3 Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95.
4 Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523.
5 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
6 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
7 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
8 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
9 Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
10 Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402.
11 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
12 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
13 Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2005 Oct;33(10):1477-81.
14 Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics. 2010 Mar 1;4:1-8.
15 Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
16 Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
17 Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
18 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
19 Primovist, Eovist: what to expect? J Hepatol. 2012 Aug;57(2):421-9.
20 Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
21 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
22 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
23 Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8.
24 Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
25 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
26 Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72.
27 Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
28 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
29 Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol. 2011 Apr;54(4):738-45.
30 Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006 Jul;34(7):1109-15.
31 Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res. 2008 Jun 1;14(11):3312-8.
32 Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54.
33 Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006 May;91(1):140-9.
34 Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos. 2010 Jul;38(7):1024-8.
35 Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
36 Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63.
37 Analysis of amino acid residues in the predicted transmembrane pore influencing transport kinetics of the hepatic drug transporter organic anion transporting polypeptide 1B1 (OATP1B1). Biochim Biophys Acta. 2016 Nov;1858(11):2894-2902.
38 Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8.
39 OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9.
40 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
41 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
42 Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos. 2008 Apr;36(4):796-805.
43 Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):585-611.
44 Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology. 2001 Nov;121(5):1185-90.
45 Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001 Mar 30;276(13):9626-30.
46 Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J. 2003 May 1;371(Pt 3):897-905.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.